Tuesday, October 16, 2012

Stocks In News (AEGR, LLY, KO, TSLA, THLD)

Aegerion Pharmaceuticals Inc (NASDAQ:AEGR)surged up 6.07% to $18.51.According to report fromReuters, U.S. drug reviewers were positive on Aegerion Pharmaceuticals's experimental drug for lipid disorder and said it showed a greater reduction in bad cholesterol as compared with statins. The FDA said an approval of the drug would require a risk evaluation and mitigation strategy to ensure that the benefits of lomitapide outweigh the risk of serious liver injury.

Eli Lilly & Co (NYSE:LLY) went up 0.61% to $52.85.Eli Lilly & Co was upgraded from market perform rating to outperform rating in a research report. Recently, r the company said that trials on a drug for treating stomach cancer had met the goals of improved patient survival and progression-free survival in a late-stage study that compared it to a dummy treatment.

The company said in a statement that the most common side effects for the medicine, ramucirumab, were high blood pressure, diarrhoea and headache.

The drug was tested in patients with gastric cancer that had spread to other parts of the body.

The Coca-Cola Company(NYSE:KO) soared 0.18% to $38.20 on a traded volume of 189k shares.Coca-Cola Hellenic Bottling SA intends to move its main stock listing from Athens to London as Greece’s largest company by market value flees the epicenter of Europe’s debt crisis.Coca-Cola Hellenic Bottling SA isthe world’s second-largest Coca-Cola bottler.The move will make it eligible for inclusion in the benchmark FTSE 100 Index.

Tesla Motors Inc(NASDAQ:TSLA) went up 0.37% to $27.43. The Company has received a $10 million grant from California to buy assembly equipment and add 500 workers to build a rechargeable sport-utility vehicle in the state.

Threshold Pharmaceuticals Inc (NASDAQ:THLD) surged up 9.33% to $5.74 on a traded volume of 54k shares.The U.S. Food and Drug Administration reached agreement with a Threshold partner covering a special protocol assessment for a Phase 3 trial of TH-302. This will allow the Companies to push forward the study of the pancreatic cancer drug.TH-302 is a potential treatment of metastatic or locally advanced unresectable pancreatic cancer

No comments:

Post a Comment

Privacy Policy | Legal Disclaimer